Health authorities in England are offering a free prescription for an experimental drug that could help relieve migrainous headaches.

Dr. Matthew A. Williams, head of the National Heart, Lung, and Blood Institute (NHLBI), said the drug, called Gynoxol, is a non-surgical therapy that is intended to improve the heart’s function by reducing inflammation.

“If it works, it could potentially be a very effective treatment for migra.

But until then, we need to get more patients to a clinical trial,” he told ABC News.

Gynoxoride, which is used in many other heart and muscle disorders, is an anabolic steroid that is manufactured by the US pharmaceutical company Novartis.

It works by increasing the level of a hormone called the growth hormone receptor, which stimulates the body to produce more protein and less fat.

The hormone also acts as a stress reducer.

Gym-goers can take it in capsules, tablets, sprays or ointments.

Williams said he is not sure how long the drug will be available to the public, but that it is likely to be available within the next year.

“We are looking at whether there are any potential complications,” he said.

“In the meantime, we can’t wait for the FDA to approve it.”

Doctors say it could be an effective treatment to relieve migra, migrainitis and other heartburn conditions, but some of those patients may have to wait longer to be tested.

Gwynoxorides’ use has been on the rise in recent years.

The drug has been approved by the Food and Drug Administration (FDA) for use in treating migrainic symptoms such as headaches, migraes, nausea, vomiting, dizziness and a feeling of being tired.

The American Heart Association recommends the medication for people with migraine headaches and migraine-related symptoms.

Gysol is a steroid, which means it contains the amino acid cysteine, which has been shown to increase the production of growth hormone, or IGF-1, a hormone that helps build muscle and help control muscle atrophy.

There are no clinical trials yet of the drug for migraine sufferers, Williams said.

Gynaecologist Dr. Peter S. Gysol, who works with migrainesis sufferers at the National Women’s Centre, said the treatment could be very effective for migranes.

“I would hope that people would see this as a viable treatment and that they would be able to get it, and I think we would be quite pleased with the results,” he explained.

“It’s a very promising approach, and it’s a drug that is well known and approved by both the FDA and the National Institute of Health and Care Excellence (NICE) and so it could easily be available in the next two to three years.”

Gyno-C-101, a generic version of the same drug that was approved by NICE, has also been shown in clinical trials to reduce symptoms of migrainias.

However, Williams warned against taking Gyno C-101 if you are on a very low dose of IGF-I medication.

“The IGF-11 is a hormone, it can be used for a very short time, so the IGF-10 will be needed,” he added.

If you take too much IGF-14, which isn’t known to be harmful to your health, it will be a lot more likely to cause migrainas.”